Insmed Incorporated (INSM) NASDAQ

103.73

-2.3(-2.17%)

Updated at June 02 04:00PM

Currency In USD

Insmed Incorporated

Address

700 US Highway 202/206

Bridgewater, NJ 08807

United States of America (the)

Phone

908 977 9900

Sector

Healthcare

Industry

Biotechnology

Employees

1271

First IPO Date

June 01, 2000

Key Executives

NameTitlePayYear Born
William H. LewisPresident, Chief Executive Officer & Chairman2.47M1969
Eugene J. Sullivan FCCPChief Product Strategy Officer593,0801965
S. Nicole SchaefferChief People Strategy Officer660,8101968
Sara BonsteinChief Financial Officer1.12M1981
Michael Alexander SmithChief Legal Officer & Corporate Secretary1.14M1978
Roger AdsettChief Operating Officer1.19M1969
Martina FlammerChief Medical Officer1.22M1964
Claire MulhearnVice President of Corporate Communications0N/A
Kevin MangeChief Development Officer0N/A
Neil HughesGM & Head of Europe, Middle East and Africa0N/A
Adele DeeringSenior Vice President of Portfolio Strategy & Operational Excellence0N/A
Christie CamelioChief Compliance Officer0N/A
Brian K. KasparChief Scientific Officer01974
Bryan DunnVice President of Investor Relations0N/A

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.